Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone aceton…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
Sector Update: Health Care Stocks Advance Late Afternoon Health care stocks rose late Monday afternoon, with the NYSE Health Care Index adding 0.3% and the H | ||
Key medical device brand for files Chapter 11 bankruptcy Investors struggle with valuation on health care and medical companies, since having drugs and treatments in various stages of testing does not guarantee approval. And it's more complicated than that because even getting a drug or treatment through FDA trials and receiving approval does not mean it ... | ||
Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Lags Revenue Estimates Clearside Biomedical (CLSD) delivered earnings and revenue surprises of -70.15% and -23.57%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock? | ||
Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Lags Revenue Estimates Mersana Therapeutics (MRSN) delivered earnings and revenue surprises of -4.86% and -18.85%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock? | ||
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Beats Revenue Estimates Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of -5.26% and +15.42%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock? | ||
AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Tops Revenue Estimates ABCELLERA BIOLG (ABCL) delivered earnings and revenue surprises of -11.76% and +35.31%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock? | ||
How Recent Moves Are Rewriting the Story for Clearside Biomedical Clearside Biomedical has seen a dramatic increase in its consensus analyst price target, rising from $4.00 to $60.00 in a short span of time. This change comes amidst heightened uncertainty, as recent strategic announcements and challenges in the financing environment have shifted analysts' outlooks. Stay tuned to discover how you can continue following these rapid developments in Clearside's evolving market story. What Wall Street Has Been Saying Recent analyst commentary has reflected a... | ||
Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Beats Revenue Estimates Clearside Biomedical (CLSD) delivered earnings and revenue surprises of +50.00% and +87.07%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock? | ||
Compugen (CGEN) Reports Q2 Loss, Lags Revenue Estimates Compugen (CGEN) delivered earnings and revenue surprises of -14.29% and -76.15%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock? | ||
Top Midday Gainers Abivax (ABVX) shares catapulted 555% amid heavy trading after the company said late Tuesday its inve | ||